Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press30910.36691/RJA309ArticlesСтатьиReview ArticleVaccination of patients with primary immunodeficiencies: a modern view on the problemВакцинация больных с первичными иммунодефицитами: современный взгляд на проблемуLatyshevaT VЛатышеваТатьяна Васильевнаtvlat@mail.ruLatyshevaE AЛатышеваЕ АMantoI AМантоИ АKostinovaA MКостиноваА МInstitute of ImmunologyФГБУ «ГНЦ Институт иммунологии» ФМБА России15062017143VOL 14, NO3 (2017)ТОМ 14, №3 (2017)192610032020Copyright ©; 2017, Pharmarus Print MediaCopyright ©; 2017, Фармарус Принт Медиа2017Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/309

Vaccination in patients with primary immunodeficiencies (PID) remains a subject of serious discussion. 20 years ago it was thought that vaccination could cause unacceptable harm to patients’ with PID, so immunization with any vaccine was strictly prohibited. Later this position was softened, when it had turned out that the risk of adverse events developing for most of the vaccines patients with PID is not higher than of the rest population. Nevertheless, it was supposed that immunization of these patients was useless because of patients’ inability to form a post-vaccination immunity. Only for the last 10 years due to new researches and accumulated experience an attitude towards vaccination in patients with PID has been radically changed. Nowadays there is only a small range of vaccines is strictly prohibited to use, while immunization against some infections is strongly recommended by the world community.

Вакцинация больных первичными иммунодефицитами (ПИД) на сегодняшний день остается предметом серьезных дискуссий. Еще 20 лет назад считалось, что вакцинация может нанести непоправимый вред пациенту с ПИД, поэтому иммунизация любыми видами вакцин была запрещена. Затем позиция несколько смягчилась, так как стало понятно, что риск развития нежелательных явлений на большую часть вакцин у пациентов с ПИД не выше, чем в основной популяции, однако предполагалось, что вакцинация этой когорты больных нецелесообразна, так как пациенты не способны формировать поствакцинальный иммунитет. И только в течение последних 10 лет благодаря новым исследованиям и накопленному опыту отношение к вакцинации пациентов с ПИД начало коренным образом меняться. В настоящее время строго запрещена вакцинация лишь ограниченным спектром вакцин, а проведение иммунизации рядом вакцин, напротив, настоятельно рекомендуется мировым сообществом.

primary immunodeficiencyvaccinationprevention of infectioninfectionsimmunoglobulins for intravenous administrationIVIGпервичный иммунодефицитвакцинацияпрофилактика инфекцийинфекциизаместительная иммунотерапияиммуноглобулины для внутривенного введенияВВИГАллергология и иммунология. Национальное руководство, краткое издание. Под ред. Р.М. Хаитова и Н.И. Ильиной. М., «Гэотар-медиа». 2013, с. 300-386.Chapel H. Primary Immune Deficiencies - Principles of Care. Front. Immunol. 2014, v. 5, p. 627.Al-Herz W., Bousfiha A., Casanova J.L. et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front. Immunol. 2014, v. 5, p. 162.Bonilla F.A., Khan D.A., Ballas Z.K. et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J. Allergy Clin. Immunol. 2015, v. 136, p. 1186-1205.Papadopoulou-Alataki E., Hassan A., Davies E.G. Prevention of infection in children and adolescents with primary immu nodeficiency disorders. Asian Pac. J. Allergy Immunol. 2012, v. 30, p. 249-258.Frenzel W., Wietek S., Svae T.E. et al. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trial. Int. J. Clin. Pharmacol. Ther. 2016, v. 54, p. 847-855.Аллергология и иммунология. Национальное руководство, краткое издание. Под ред. Р.М. Хаитова и Н.И. Ильиной. М., «Гэотар-медиа». 2013, с. 152-155.Медуницын Н.В. Вакцинология. «Триада Х». М., 2010, с. 288-290.Eibl M.M., Wolf H.M. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. Immunotherapy. 2015, v. 7, p. 1273-1292.Principi N., Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine. 2014, v. 32, p. 3725-3731.Goldacker S., Draeger R., Warnatz K. et l. Active vaccination in patients with common variable immunodeficiency (CVID). Clin. Immunol. 2007, v. 124, p. 294-303.Canadian Immunization Guide, Seventh Edition - 2006, Text prepared by the National Advisory Committee on Immunization Published by the Public Health Agency of Canada Infectious Disease and Emergency Preparedness Branch Centre for Infectious Disease Prevention and Control under the authority of the Minister of Public Works and Government Services Canada, p. 117-130.Rubin L.G., Levin M.J., Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis. 2014, v. 58, p. 44-100.Shearer W.T., Fleisher T.A., Buckley R.H. et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close-contacts: Medical Advisory Committee of the Immune Deficiency Foundation. The Journal of Allergy and Clinical Immunology. 2014, v. 133, p. 961-966.Marciano B.E., Huang C.Y., Joshi G. et al. BCG vaccination in SCID patients: complications, risks and vaccination policies. The Journal of allergy and clinical immunology. 2014, v. 133, p. 1134-1141.Shaghaghi M., Shahmahmoodi S., Abolhassani H. et al. Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995-2014. Emerging Infectious Diseases. 2016, v. 22, p. 1712-1719.Shaghaghi M., Parvaneh N., Ostad-Rahimi P. et al. Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature. Immunol Invest. 2014, v. 43, p. 292-298.Shahmahmoodi S., Mamishi S., Aghamohammadi A. et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995-2008. Emerg. Infect. Dis. 2010, v. 16, p. 1133-1136.Parvaneh N., Shahmahmoudi S., Tabatabai H. et al. Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency. J. Clin. Virol. 2007, v. 39, p. 145-148.Conti F., Lugo-Reyes S.O., Blancas Galicia L. et al. Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases. J. Allergy Clin. Immunol. 2016, v. 138, p. 241-248.Saul L.R., Lizbeth B.G., Jacinta B. 135 Mycobacterial Infections in cChildren With Chronic Granulomatous Disease World Allergy Organization Journal. 2012, v. 5, p. 62.Goldacker S., Draeger R., Warnatz K. et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin. Immunol. 2007, v. 124, p. 294-303.Pedersen G., Halstensen A., Sjursen H. et al. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand. J. Immunol. 2011, v. 74, p. 210-218.Rezaei N., Siadat S.D., Aghamohammadi A. et al. Serum bactericidal antibody response 1 year after meningococcal polysaccharide vaccination of patients with common variable immunodeficiency. Clin. Vaccine Immunol. 2010, v. 17, p. 524-528.Hanitsch L.G., Löbel M., Mieves J.F. et al. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. Vaccine. 2016, v. 5, p. 2417-2423.Paroli M., Accapezzato D., Francavilla V. et al. Long-lasting memory-resting and memory-effector CD4+ T-cells in human X-linked agammaglobulinemia. Blood. 2002, v. 99, p. 2131-2137.